Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 15

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 15
---
 factors                    |     | Investing in the Common Shares involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to invest in the Common Shares.                                    |
| Nasdaq Capital Market           |     | “CMND”                                                                                                                                                                                                                                                                                                                                                                                              |
| Frankfurt Stock Exchange symbol |     | “CSE”                                                                                                                                                                                                                                                                                                                                                                                               |

Unless otherwise stated, all information in this prospectus is based on 16,671,256 Common Shares outstanding as of November 14, 2025, and does not include the following as of that date:

| ● | 11,927,606 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from $0.20 to $243.75, all of which were vested as of such date; |
| ● | 5,521 common shares                                                                                                                                                                      
 issuable upon the exercise of options to directors, employees and consultants under our incentive option plan outstanding as of such                                                     
 date, at a weighted average exercise price of $429.24, of which 5,513 were vested as of such date; and                                                                                   |
| ● | 76,251 common shares issuable upon the exercise of RSUs issued to consultants under consulting agreements.                                                                               |

<div align='center'>S-5

RISK FACTORS</div>

Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks described below and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, together with all of the other information appearing in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein, including in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks we face. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations and become material. Our business, financial condition and results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements; you should read the explanation of the qualifications and limitations on such forward-looking statements discussed elsewhere in this prospectus supplement under the caption “Cautionary Statement Regarding